Psychedelics

Alert – New Resource – Are you planning to apply for a psilocybin facilitator, service center, manufacturer, or testing lab license in Oregon?

Published

1 year ago

February 12, 2023

admin

Greetings,

Are you planning to apply for a psilocybin facilitator, service center, manufacturer, or testing lab license in Oregon? Did you know that required operational forms and documents are now available in both English and Spanish on the Oregon Psilocybin Services (OPS) website?

In case you missed it, OPS also posted Social Equity Plan Resources to provide support to applicants on building effective social equity plans.

We also have fact sheets for each of the four license types, which are available in English and Spanish:

We are now one month into accepting applications for licensure. Our team has been working to provide support to those who are working through the application process as well as responding to many questions from future applicants and members of the public.

As of today, we have received the following number of submitted applications in the Training, Licensing, and Compliance (TLC) system:

Facilitator applications: 0

Service Center applications: 4

Manufacturer applications: 10

Laboratory applications: 2

Worker Permit applications: 116

In addition to submitted applications, we have many pending applications in the system. Pending applications may have been started in the TLC system but have not yet been submitted for OPS review. We understand it may take time for applicants to work through certain requirements before submitting their applications for OPS review. For example, before applying for facilitator licenses, students may still be finishing their psilocybin facilitator training programs. Those who intend to apply for service center and manufacturer licenses may be working with local governments on land use compatibility issues. And those who intend to apply for laboratory licenses may be working through the accreditation process.

Once submitted, applications take time to review and approve. We may be working with applicants on providing additional information or missing documents, waiting for the background check processes to be completed, and conducting site inspections for service center, manufacturer, and testing lab applications.

We want to thank you for bringing questions. We hope to issue our first licenses in the next couple of months and will keep you updated!

With Gratitude,

The Oregon Psilocybin Services Team
www.oregon.gov/psilocybin

Source link

Psychedelics

Lykos In Patent Mode On MDMA

Published

3 weeks ago

July 5, 2024

admin

We don’t believe in taking out IP on MDMA

oh actually we do

Double Blind

In a shocking move that contradicts its previous stance on intellectual property, Lykos Therapeutics (formerly known as MAPS PBC) — the organization leading the movement to legalize MDMA–assisted therapy — has filed multiple patent applications for specific forms and formulations of MDMA. Prior to this revelation, which was first reported on by Psychedelic Alpha, Lykos had long been praised in the psychedelic community and media for its “altruistic stance” in not seeking patent protections as part of its strategy, instead choosing to publish its research findings in scientific literature.

MAPS’s anti-patent stance, which intended to prevent MDMA from being monopolized, stood in stark contrast to the aggressive patent strategies of competitors like Compass Pathways and Atai Life Sciences. Rick Doblins, the founder of MAPS, had been analyzing the non-patentable status of MDMA since the late ‘80s, and in an article titled “MDMA Patentability and Orphan Drug Designation,” published in 1992, he wrote:

“It could be a major setback if MAPS funded MDMA research and secured approval for its medical use only to have someone else control it through an inexpensively obtained use patent.”

Read more

Lykos Therapeutics Quietly Moves to Patent MDMA

Source link

Psychedelics

Press Release: PsychedelicNewsWire Named Official Media Sponsor of the 4th Annual Psychedelic Therapeutics and Drug Development Conference

Published

2 months ago

May 18, 2024

admin

LOS ANGELES, May 17, 2024 (GLOBE NEWSWIRE) — PsychedelicNewsWire (“PNW”), a specialized communications platform for the psychedelics sector and one of the 60+ brands powered by IBN (“InvestorBrandNetwork”), is pleased to announce that it will be the Official Media Sponsor for the 4^th Annual Psychedelic Therapeutics and Drug Development Conference (“the conference”), an industry flagship event dedicated to research and development of psychedelics in the healthcare space hosted by Arrowhead SciTech Conferences & Events (“Arrowhead”). The event will be held at the iconic Revere Hotel Boston Common, 200 Stuart Street, Boston, MA 02116 on 23-24 May 2024

Source link

individualized treatment

Risks of Psychedelics for People with Personality Disorders

Published

3 months ago

May 9, 2024

admin

While psychedelics have shown promise in treating certain mental health conditions, a recent study suggests they may pose risks for individuals with personality disorders. The findings underscore the importance of careful screening and personalized approaches in psychedelic-assisted therapy.

Navigating the Psychedelic Landscape: Potential Risks for Individuals with Personality Disorders

Psychedelics, including substances like psilocybin and LSD, have gained significant traction in recent years for their potential therapeutic benefits in treating mental health conditions such as depression, anxiety, and PTSD. However, a recent publication in the Journal of Psychopharmacology has raised concerns about the suitability of these substances for individuals with personality disorders.

The study surveyed individuals who had used psychedelics and who were also diagnosed with personality disorders. A considerable number of respondents reported negative and persistent psychological impacts following their psychedelic experiences. Notably, these included heightened anxiety, paranoia, mood instability, and an exacerbation of existing personality disorder symptoms.

Researchers suggest that the vulnerability of individuals with personality disorders to the adverse effects of psychedelics may stem from pre-existing challenges in emotional regulation, self-identity, and interpersonal relationships. The profound and introspective nature of psychedelic experiences can intensify these issues, potentially leading to psychological distress and symptom aggravation.

This research highlights the critical need for thorough screening and assessment in the context of psychedelic-assisted therapy. It suggests that individuals with personality disorders might require tailored therapeutic approaches and robust support systems to navigate potential risks and to secure safe and positive outcomes.

Why It Matters

The burgeoning interest in psychedelic therapy underscores the necessity to discern both the potential benefits and risks across different demographic groups. This study contributes valuable insights, particularly for clinicians and researchers, stressing the importance of personalized treatment plans and the cautious consideration of individual vulnerabilities when administering psychedelic-assisted therapy.

Potential Implications

The findings from this study emphasize the need for ethical and responsible practices within the field of psychedelic-assisted therapy. There is a pressing requirement for the development of detailed screening protocols that can identify individuals who may be more susceptible to the adverse effects of psychedelics. Furthermore, crafting specialized therapeutic strategies that cater specifically to the needs of individuals with personality disorders is essential for ensuring their safety and overall well-being during and after undergoing psychedelic experiences.

The Bigger Picture

The debate surrounding the therapeutic use of psychedelics is complex, with various factors influencing the suitability of these treatments for different individuals. While there are promising results in general populations, the nuanced needs and potential vulnerabilities of those with personality disorders require careful consideration to prevent harm and maximize therapeutic outcomes. This necessitates ongoing research, improved clinical protocols, and a commitment to patient-centered care in the burgeoning field of psychedelic medicine.

Source: Science Alert

Source link